Myriad Announces Publication of Vectra® Study in Journal Rheumatology
SALT LAKE CITY, Dec. 26, 2018 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a global leader in personalized medicine, today announced the results from a large commercial cohort and several clinical studies on development of the adjusted Vectra …